Skip to main content
. 2020 Jun 3;117(24):13428–13436. doi: 10.1073/pnas.2001569117

Fig. 5.

Fig. 5.

iTPNCs suppress tumor growth via an abscopal effect. (A) Schematic of experimental design to test abscopal effects. Anti-CTLA4 checkpoint inhibitor antibody was administered intraperitoneally into each mouse bearing bilateral B16F10 s.c. flank tumors. Unencapsulated ODN 1826 (naked), or ODN 1826 iTPNCs were injected intratumorally into the ipsilateral (Ipsi) tumor, and both the ipsilateral and contralateral (Contra) tumors were measured. Tumors were injected on days indicated by pink arrowheads, and antibody treatment was continued for the length of the study. (B) Plots show the final tumor volume relative to tumors in mice treated only with anti-CTLA4 antibody. The two Left plots show the volume of the ipsilateral, intratumorally injected tumor, and the two Right plots show the volume of the contralateral, noninjected tumor. (*P = 0.0337, one-way ANOVA with Tukey’s multiple comparisons test, n = 9 tumors per group, error bars ± SEM, data are representative of three independent experiments). (C) Representative images of tumors from each of the treatment groups from B. (Scale bars, 2 mm.)